Open Access
Biomarkers in heart failure
Giuseppina Novo1,Gisella Rita Amoroso1,Giovanni Fazio1,Fiorella Sutera1,Salvatore Novo1
Chair and Division of Cardiology, Department of Internal Medicine and Cardiovascular Disease, University of Palermo, Palermo, Italy.
DOI: 10.2741/3391 Volume 14 Issue 7, pp.2484-2493
Published: 01 January 2009
(This article belongs to the Special Issue Progresses in heart failure diagnosis and treatment)

Nowadays, heart failure (HF) has an increasing prevalence, particularly in the elderly, and is becoming a clinical problem of epidemic proportion in terms of morbidity and mortality. Developing biological markers, that can aid in the diagnosis of HF and in the differentiation of congestive heart failure (CHF) from other causes of dyspnoea, will reduce the cost of health care. However, an ideal biomarker has not yet been identified. Potential markers of HF include neuro-hormonal mediators, markers of myocyte injury, and indicators of systemic inflammation. Among these, the BNP and NT-pro-BNP are the most widely studied and appear to be useful in patients with dyspnoea of unknown aetiology, and for risk assessment of patients with established HF. However these markers should be used as an addition tool, and not as a substitute of clinical assessment.

Share and Cite
Giuseppina Novo, Gisella Rita Amoroso, Giovanni Fazio, Fiorella Sutera, Salvatore Novo. Biomarkers in heart failure. Frontiers in Bioscience-Landmark. 2009. 14(7); 2484-2493.